Endstage Renal Disease Clinical Trial
Official title:
Data Collection for Next Generation Ultrasound Technology Development
Verified date | March 2018 |
Source | GE Healthcare |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is designed to collect data from a ultrasound device being used to evaluate feasibility of next generation algorithms for ultrasound data processing and does not test any health outcome.
Status | Completed |
Enrollment | 142 |
Est. completion date | December 6, 2016 |
Est. primary completion date | December 6, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Are adults (aged 18 years of age or older) at the time of consent; 2. Are undergoing maintenance hemodialysis (MHD); AND 3. Are able and willing to provide written informed consent for participation Exclusion Criteria: 1. Have anatomical characteristics or comorbid medical conditions that prevent completion of ultrasound scanning using the study device; OR 2. Are potentially put at additional risk by participating, in the opinion of the investigator. |
Country | Name | City | State |
---|---|---|---|
United States | Research By Design | Evergreen Park | Illinois |
Lead Sponsor | Collaborator |
---|---|
GE Healthcare |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Diagnostic Ultrasound Exams | Collection (number) of ultrasound images representative of sonographic findings routinely observed in the general imaging population. | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03023748 -
Intravenous Paricalcitol in Chronic Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00745914 -
Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients
|
N/A | |
Terminated |
NCT00776191 -
Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism
|
Phase 4 | |
Completed |
NCT02981706 -
Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis
|
N/A | |
Completed |
NCT02966028 -
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
|
Phase 2 | |
Completed |
NCT02976246 -
Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients
|
Phase 4 | |
Recruiting |
NCT02957877 -
LMWH Infusion as Anticoagulation for Home HD
|
Phase 4 | |
Completed |
NCT00745719 -
Parathyroidectomy in Endstage Renal Disease
|
N/A | |
Completed |
NCT03010072 -
The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum
|
Phase 2 | |
Recruiting |
NCT03020303 -
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
|
Phase 3 | |
Completed |
NCT00745589 -
Sevelamer Hydrochloride in Peritoneal Dialysis Patients
|
N/A | |
Not yet recruiting |
NCT02976688 -
Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis
|
Phase 2/Phase 3 | |
Completed |
NCT02970201 -
Improving Adherence in Renal Dialysis Patients Through Electronic Interventions
|
N/A | |
Withdrawn |
NCT00502268 -
Vitamin D and Carboxy PTH Fragments in Coronary Calcification
|
Phase 4 | |
Completed |
NCT02977117 -
The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis
|
Phase 2 | |
Completed |
NCT02207153 -
Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients
|
||
Completed |
NCT02866214 -
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03054454 -
A Podiatry Led MDT Intervention to Reduce the Burden of Foot Disease in Patients With End Stage Kidney Failure
|
N/A |